Key facts
- Forth Therapeutics’s last known valuation is $7.1M (Mar 2025).
- It has raised $4.7M; the latest was Early Stage VC ($4.7M) in Mar 2025.
- Notable investors include Sofinnova Partners, Old College Capital, The University of Edinburgh.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Forth Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Forth Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Forth Therapeutics
Operator of a biotechnology company intended to develop precision treatments for fibrotic disease. The company's platform uses advanced computational models and machine learning algorithms to combine single-cell and spatial genomics approaches to identify antifibrotic targets with high precision, enabling researchers to create a high-definition map of fibrotic disease, accelerating precision drug discovery and development.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 9
- Website
- forthtx.com/
- Ownership
- Privately Held (backing)
Forth Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Forth Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Forth Therapeutics in its N-PORT filings yet. We sweep new filings monthly.